Testing IMV101 for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- Your lymphoma must be a type that affects B cells (like DLBCL, FL, or MCL) and have the CD19 marker on the cancer cells
- Your lymphoma has come back or not responded after at least two prior treatments, including specific types of chemotherapy and immunotherapy
- You have at least one tumor that can be measured on scans (a lymph node larger than 1.5 cm or another area larger than 1 cm)
- You are generally well enough to be up and about (ECOG score 0 or 1), and your organs (kidneys, liver, bone marrow) work well enough on blood tests
- You are not pregnant or breastfeeding, and if you could become pregnant, you must use reliable birth control for 12 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
This study tests a new treatment called iMagic for people with blood cancers like non-Hodgkin lymphoma or multiple myeloma that have come back or stopped responding to standard treatment. The goal is to see if it is safe and can help control the cancer.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests an experimental drug called MTM-H-001 given as an injection. It's for people with B-cell lymphoma that has returned or not responded to standard treatments, and it aims to see if the drug can help control the cancer.
This trial tests whether IM19 can safely and effectively treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It is for adults with certain lymphoma markers and good overall functioning.
Hear when a new Relapsed/Refractory B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.